Acute traumatic coagulopathy affects 20% to 30% of trauma patients, but the extensive collinearity of the coagulation cascade complicates attempts to clarify global clotting factor dysfunction. This study aimed to characterize phenotypes of clotting factor dysfunction and their contributions to mortality after major trauma.
T rauma is the primary cause of mortality in those younger than 47 years, and hemorrhage is the second leading cause of trauma-related deaths, surpassed only by central nervous system injury.
1,2 A majority of deaths from hemorrhage arise within the first 24 hours. An endogenous form of coagulopathy, termed acute traumatic coagulopathy (ATC), affects 20% to 30% of patients immediately after injury and is believed to contribute to early hemorrhagic death. Acute traumatic coagulopathy occurs independently of the iatrogenic dilutional coagulopathy elicited by resuscitation efforts and has been associated with poorer outcomes, notably larger fluid resuscitation requirements, prolonged intensive care unit stays, and higher overall mortality rates. [3] [4] [5] Prior work has shown the pathophysiology of ATC reflects overall global clotting factor dysfunction; however, the individual clotting factor roles in the development of this coagulopathy are not well defined. 6, 7 Uncovering the key individual factors in ATC could allow development of targeted therapies aimed at blunting the effect of early coagulopathy. The clotting cascade is highly interrelated, and elucidating the individual factor contributions to ATC requires a statistical approach that can overcome the extensive collinearity of the clotting factors. This interdependence of the factors renders traditional parametric techniques problematic and insufficient to truly understand mechanistic drivers and outcome-defined phenotypes of ATC. In contrast, nonparametric techniques such as principal component analysis (PCA) allow for examination of highly collinear data and have been used by our group in small analysis and others in a proof-of-concept manner to examine coagulation after injury. 7, 8 Preliminary work by our group examined PCA for assessing the role of individual clotting factors in the development of ATC in 2013. Among a 163-person cohort studied, complete coagulation data were available on only 88 patients, and the PCA approach identified three potential coagulopathic phenotypes as major factors for ATC. 7 Only two of the three phenotypes were associated with increased mortality, including one representing global clotting dysfunction (of prothrombin, factors V, VII, VIII, IX, X, protein C, and antithrombin III) and the other representing activation of protein C and fibrinolysis. Although the earlier work remains promising, the sample size was small, and PCA is most effective in larger sample sizes to better define the relationships between interrelated variables. Utilizing a larger, more complete cohort, we hypothesized that PCA would confirm specific coagulopathic phenotypes important in ATC.
METHODS
This study investigates the association of individual coagulation factors to mortality in adult trauma patients of the highest activation level presenting to San Francisco General Hospital between February 2005 and February 2015 and who were enrolled into the prospective Activation of Coagulation and Inflammation in Trauma ongoing cohort study. Enrolled patients include those in whom demographic, clinical, and laboratory data were collected on admission and in-hospital mortality status was assessed at 6 hours, 24 hours, 28 days, and discharge. Those younger than 15 years, who had greater than 20% burns, or who were pregnant, incarcerated, or transferred from outside hospitals were excluded. Efforts were made to obtain Time 0 (emergency department [ED]) blood samples in patients eligible for enrollment. Study design and implementation were completed with approval from the institutional review board at the University of California, San Francisco, School of Medicine.
Coagulation factors including factors II, V, VII, VIII, IX, and X and protein C percent activity were measured on patients at Time 0 having an available blood sample. An international normalized ratio (INR) of 1.3 or greater was selected to denote coagulopathy according to previous multicenter discrimination analysis by Kutcher et al. 9 identifying patients receiving increased packed red blood cells in the first 24 hours, as well as formal laboratory definitions of coagulopathy found in the literature. [9] [10] [11] Univariate logistic regression was performed to assess predictors of 28-day mortality using factor levels. Those with a significance of p ≤ 0.20 were selected for multiple logistic regression modeling of 28-day mortality controlling for age, mechanism of injury, base excess, and traumatic brain injury (TBI). Significance was determined at the p < 0.05 level for independent predictors of 28-day mortality. Model fit was assessed by area under the receiver operating characteristic curves.
Principal component analysis was utilized for further examination of coagulopathic phenotypes, with factors II, V, VII, VIII, IX, and X and protein C selected as predictor variables. Principal component analysis is a data-driven statistical technique aimed at dimensionality reduction, simplifying largevolume, collinear data by maximizing the variance along new linear coordinate axes. 12 In contrast to interaction terms that can result in a tremendous loss of information, PCA restructures the data according to the most fundamental components of the population. These axes or principal components individually represent unique patient phenotypic subgroupings and can be used to interpret data much more efficiently. Principal component analysis defines patterns in the data and then expresses these as principal components or phenotypes, to illustrate similarities and differences between the various phenotypes driving outcome. Sampling adequacy was assessed using the Kaiser-Meyer-Olkin test. Eigenvalues distinguish meaningful principal components or phenotypes, and those with more than 1 were deemed significant in concordance with the Kaiser rule. Loading values quantify variable contribution to each principal component, and those greater than 0.30 were considered significant. Promax rotation, a form of oblique principal component transformation, was utilized for improved data interpretability, and results were visualized graphically by loading plots and score plots. Continuous phenotype scores were calculated for each patient and included in multiple logistic regression controlling for age, mechanism of injury, base excess, and TBI. Patients were stratified by mortality status at 6 hours, 24 hours, 28 days, and discharge, and phenotype scores of living and deceased cohorts were compared by the Wilcoxon rank-sum test. Lastly, the upper and lower quartiles of phenotype scores were examined for differences in demographic, clinical, and laboratory variables by χ 2 and Wilcoxon rank-sum tests. Outcomes evaluated included age, body mass index, gender, Injury Severity Score (ISS), Glasgow Coma Scale (GCS) score, temperature, base excess, systolic blood pressure, mechanism of injury, TBI, INR, partial thromboplastin time (PTT), platelets, hemoglobin, and mortality at 28 days.
RESULTS
Complete coagulation factor data were available for 876 (61%) of 1,429 patients, of whom 81% were male, 34% were white, and the median age was 35 years old. Median ISS was 16, with 57% experiencing blunt injury and 39% experiencing TBI. Fourteen percent were coagulopathic on ED arrival (as defined by INR ≥1.3), and overall mortality at 28 days was 19% (Table 1) .
In univariate analysis, dysfunction of clotting factors II, V, VIII, IX, and X and protein C on admission were significantly associated with mortality at 6 hours, 24 hours, 28 days, and discharge ( Table 2 ). Dysfunction of factor VII was similarly predictive of increased mortality at 6 hours, but this effect diminished starting at 24 hours and persisted for all subsequent time points.
Coagulation factors remain linearly correlated, with factors II and VII, II and IX, II and X, VII and X, and IX and X exhibiting the highest correlation coefficients (see Table, Table 1) . For every 10% decrease in the activity of factors V, VIII, and X, there were 14%, 3%, and 21% increases in the odds of mortality, respectively.
To overcome the difficulties with collinearity incumbent in a sequential protease activation sequence such as the clotting cascade, we explored coagulopathic phenotypes after trauma using PCA. All coagulation factors and protein C exhibited a Kaiser-Meyer-Olkin value of greater than 0.50. Phenotypes 1 and 2 displayed eigenvalues of greater than 1.0 and collectively explained 66.3% of the data variance (Table 3) .
Phenotype 1 accounted for 49.3% of the variance, and factors II, VII, IX, and X and protein C were significant contributors (loading values >0.30). Phenotype 2 described 17.0% of the variance, and factors Vand VIII were significant contributors (loading values >0.30). In score plots with patients identified by mortality status, deceased patients demonstrated significantly decreased Phenotypes 1 and 2 scores compared with living patients that are most notable at 6 hours and persist across all mortality time points (Fig. 1) . In multiple logistic regression, only Phenotype 2 (OR, 0.55; 95% CI, 0.42-0.72) remained a significant predictor of mortality at 28 days after controlling for age, base excess, mechanism of injury, and TBI (Table 4) .
Patients in the lowest quartile of Phenotype 1 were significantly more injured than the upper quartile (ISS, 26 vs. 10; 
DISCUSSION
The precise mechanism of ATC is unknown, but one leading theory postulates that it is mediated by anticoagulant and antiinflammatory arms of the activated protein C (aPC) pathway. 4, 13, 14 Following tissue damage, thrombin binds thrombomodulin, subsequently activating protein C bound to the endothelial protein C receptor. Activated protein C works as an anticoagulant by both proteolytically cleaving coagulation factors Va and VIIIa, as well as derepressing fibrinolysis through inhibition of plasminogen activator inhibitor 1, triggering dysregulated fibrinolysis by tissue-plasminogen activator. 4, 15 Along with aPC, other likely mechanisms for ATC include factor dysfunction, fibrinolysis, and activation of other anticoagulant pathways such as antithrombin III. [16] [17] [18] Consistent with our previous work, our data here confirmed that abnormalities of coagulation factors II, V, VIII, IX, and X and protein C were significantly associated with mortality after major trauma in univariate analysis, but only factors V, VIII, and X and protein C remained significantly predictive after controlling for age, base excess, TBI, and mechanism of injury. This is consistent with the theory that protein C activation is the driving factors V and VIII dysfunction after injury. These results provide evidence supporting the crucial roles of factors V, VIII, and X to impaired hemostasis after trauma.
In addition, factor VII is the only coagulation factor not significantly associated with mortality at 28 days. While it was predictive of mortality at 6 hours, this effect was absent at all subsequent time points, thereby suggesting factor VII may be a useful component only for early mortality. Akin to events found in the CONTROL randomized clinical trial of recombinant factor VII in trauma, patients receiving recombinant factor VII demonstrated no change in mortality compared with placebo. 19 Further work to identify phenotypes associated with relative factor VII dysfunction would potentially identify patients who may benefit from rVIIa.
Principle Component Analysis
While the univariate analysis was compelling, we are acutely aware of issues with collinear data when examining a sequential coagulation activation cascade. Importantly, PCA provides a means of combating the specific complications arising from predictor variable interdependence. Reexamining the data using effective linear axes can help uncover noteworthy characteristics and overarching trends that may otherwise remain hidden within statistical noise from traditional regression. Furthermore, PCA has been previously utilized in the setting of ATC to examine the biological mechanisms of coagulopathy, as well as corresponding functional phenotypes via rapid thromboelastography. Both Chin et al. 8 and Kutcher et al. 7 identified global clotting factor abnormalities and hyperfibrinolysis to be unique processes contributing to the development of ATC. This PCA study expands the preliminary work of our group completed by Kutcher et al., but with a specific focus on clotting factor abnormalities and implemented in a much larger patient cohort.
In this analysis, we found global clotting factor dysfunction is broken into two subgroups: (1) factors II, VII, IX, and X and protein C (represented by Phenotype 1); (2) factors V and VIII (represented by Phenotype 2). Together, Phenotypes 1 and 2 account for 66.3% of the variability, and 49.3% and 17.0%, respectively. Phenotypes exhibit positive loadings of all contributing components, and accordingly, low phenotype scores denote clotting factor abnormalities (defined by decreased clotting factor or protein C percent activity). In score plots stratified by mortality status, the deceased cohort expressed significantly lower Phenotypes 1 and 2 scores compared with their living counterparts. This effect was most prominent at 6 hours, but remained significant until hospital discharge. A majority of deaths from trauma hemorrhage occur within the first 24 hours, during which the hypocoagulable early phase of ATC is most prominent. 1, 16 These findings suggest (1) global clotting factor dysfunction is most influential in the hours immediately following injury, and (2) these aftereffects are ultimately longstanding and continue to associate with mortality up to a month beyond the initial insult.
In multiple logistic regression, only Phenotype 2 remained a significant predictor of mortality at 28 days after controlling for TBI, base excess, age, and mechanism of injury. Even when accounting for the issues of collinearity, factors V and VIII continue to identify themselves as significant components to trauma outcomes. Unfortunately, no prior studies exist specifically delving into the roles of factors V and VIII in the setting of trauma. However, previous analyses of the broader ATC revealed that levels of factor V associate with hypoperfusion, and dysfunction of coagulation factors V and VIII correlates with activation of protein C. 4, 20 Factor V has been more extensively studied in nontrauma situations, including liver transplantation and shock. Zulian et al. 21 found factor V serves as an early predictor of allograft failure and death in liver transplant patients. In addition, the PROWESS trial found that heterozygous factor V Leiden carriers displayed reduced mortality in the setting of sepsis. 22 In subsequent mouse studies, Liang et al. 23 identified protein C cleaved factor Vas a crucial cofactor inhibiting a novel inflammatory tissue factor signaling pathway mediated by activated protein C. Discovery of factor V's role in a new murine protein C-mediated inflammatory pathway is exciting and insinuates that factor V may play an even larger function in dictating the balance of hypocoagulability, hypercoagulability, and inflammation after trauma. Of course, substantiation of this pathway and its interacting components must first occur in humans. Together, these works evidence the impact of factors V and VIII and their possible roles in the coordination of trauma outcomes and the inflammatory response posttrauma. Although preliminary, our work suggests that individualized phenotypes of posttrauma coagulopathy can be identified, which in the era of personalized medicine can be uniquely targeted. In the future, we speculate that perhaps targeted replacement of factors V and VIII may more effectively guide resuscitation than comprehensive nontargeted replacement via plasma. Further studies assessing clotting factor repletion after trauma would be particularly promising.
In interquartile comparisons of phenotype groups, dysfunction of clotting factors II, VII, IX, and X and protein C (low Phenotype 1) was associated with more severe injury, denoted by significantly worse ISS, GCS score, base excess, temperature, and systolic blood pressure. Intuitively, coagulation factor dysfunction should be apparent on laboratory testing, and this association was evident by elevated INR, prolonged PTT, and decreased platelets and hemoglobin. Patients also displayed a higher percentage of TBI and overall mortality. Components of Phenotype 1 encompass both intrinsic and extrinsic arms of the coagulation cascade, thus paralleling identification of global clotting factor dysfunction in prior PCAs from Chin et al. 8 and Kutcher et al. 7 In contrast, abnormalities of factors V and VIII (low Phenotype 2) was not associated with an increased level of injury, because patients with low Phenotype 2 displayed no statistical difference in ISS, base excess, temperature, or systolic blood pressure. Interestingly, despite a similar level of injury, these patients demonstrated prolonged PTT, decreased platelets, and higher overall mortality. Furthermore, individuals with low Phenotype 2 displayed an increased proportion of blunt injury. Opposed to penetrating injury, in blunt injury, kinetic energy is dispersed over a greater surface area, thus yielding more pronounced global tissue damage. With tissue factor extensively expressed by the cellular components of the vascular system and released during trauma, we surmise blunt injury may result in a greater efflux of tissue factor. [24] [25] [26] [27] The extrinsic coagulation pathway, initiated by tissue factor release, has long been considered the primary driver of hemostasis posttrauma. However, the role of tissue factor in coagulopathy is poorly understood. Moreover, the increase in thrombin-generating potential has been a puzzling aspect of protein C-mediated coagulopathy. In a previous work by our group in mouse models of trauma, ATC is facilitated by thrombin activated by the tissue factor pathway. 28 Although correlate interactions have yet to be validated in humans, this putative mechanism explains the association of factors V and VIII dysfunction with blunt injury, as well as the increased thrombin generation of protein C-mediated ATC.
Study Limitations
This study has several potential limitations. First, complete coagulation data were available for only 876 (61%) of 1,429 patients because not all patients had a Time 0 blood sample drawn. Those patients who were transported immediately to the operating room because of being in extremis were more likely to have a Time 0 sample obtained in the ED. Our clinical practice is to attempt to obtain rapidly at least one intravenous access point to get a type and cross blood sample prior to transport to the operating room. Our research samples are drawn by protocol from this same intravenous line prior to use of the line for blood products or intravenous fluids. Given this reflection of clinical practice, it is not surprising that we found individuals with nonmissing data to be more injured than their missingdata counterparts (ISS, 16 vs. 10; p < 0.001; base excess, 3.8 vs. −2.6; p = 0.0045). Although our data are missing in a nonrandom fashion, we succeeded in targeting the most severely injured patients and subsequently believe our results to be robust to elucidate trauma pathophysiology in the highest-risk patient group.
In addition, PCA as a technique possesses limited generalizability. Phenotypes are not directly clinically interpretable, and phenotype scores cannot be calculated for patients outside the original sample population. Furthermore, the need for an a priori inclusion of predictor variables opens the possibility of predictor selection bias as coagulopathy after trauma is governed by numerous proteins beyond those included in this analysis. However, we intended this study to be an exploratory investigation focused on clotting factor dysfunction immediately after injury. Identifying patterns of coagulation factors is a valuable step toward unmasking the complexities of extrinsic and intrinsic arms of the coagulation cascade posttrauma. Expanding these findings with inclusion of inflammatory mediators and thromboelastography results would be a crucial next step.
CONCLUSIONS
In summary, these findings substantiate the crucial association of factors Vand VIII on mortality following severe trauma. The complex collinearity of coagulation factors can prove difficult for standard regression techniques, but we found PCA identifies two distinct patterns within the entirety of global clotting factor abnormalities forming a theoretical basis for identification of unique phenotypes after injury, which may potentially benefit from personalized targeted treatment rather than one-size-fitsall, plasma-based hemostatic resuscitation. Both exhibit clear correlation with clinical outcomes and further evidence the impact of factors V and VIII on early and late trauma mortality. 
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